AAPL344.17-5.34 (-1.53%) ▼|ABBV288.24-6.59 (-2.24%) ▼|ABT113.60-1.91 (-1.65%) ▼|ACN265.16+0.89 (+0.34%) ▲|ADBE246.44-2.04 (-0.82%) ▼|AMAT319.25-50.15 (-13.58%) ▼|AMD404.40-84.38 (-17.26%) ▼|AMGN460.28-18.20 (-3.80%) ▼|AMT193.99-0.87 (-0.45%) ▼|AMZN260.21-5.82 (-2.19%) ▼|AVGO291.53-33.95 (-10.43%) ▼|AXP324.97-7.62 (-2.29%) ▼|BA172.50-4.50 (-2.54%) ▼|BAC49.76-1.87 (-3.62%) ▼|BKNG168.72-2.25 (-1.32%) ▼|BLK1,170.67-53.70 (-4.39%) ▼|BMY63.13-1.06 (-1.65%) ▼|BNY147.49-5.23 (-3.42%) ▼|BRK-B572.33-6.76 (-1.17%) ▼|C118.45-6.29 (-5.04%) ▼|CAT553.64-37.66 (-6.37%) ▼|CL98.69-0.07 (-0.07%) ▼|CMCSA24.95+0.10 (+0.40%) ▲|COF203.84-2.47 (-1.20%) ▼|COP135.46-1.48 (-1.08%) ▼|COST1,065.59+19.12 (+1.83%) ▲|CRM222.41-4.70 (-2.07%) ▼|CSCO95.72-7.89 (-7.62%) ▼|CVS81.33+1.37 (+1.71%) ▲|CVX212.93-4.03 (-1.86%) ▼|DE663.31-13.19 (-1.95%) ▼|DHR226.34-8.59 (-3.66%) ▼|DIS117.22-1.73 (-1.45%) ▼|DUK130.08+0.49 (+0.38%) ▲|EMR162.61-7.83 (-4.59%) ▼|FDX316.80-12.60 (-3.83%) ▼|GD356.35-8.52 (-2.34%) ▼|GE314.73-14.72 (-4.47%) ▼|GEV770.51-62.32 (-7.48%) ▼|GILD167.57-6.91 (-3.96%) ▼|GM89.33-3.10 (-3.35%) ▼|GOOG281.74-5.56 (-1.94%) ▼|GOOGL282.57-6.36 (-2.20%) ▼|GS868.95-59.05 (-6.36%) ▼|HD349.94-5.50 (-1.55%) ▼|HON215.78-12.69 (-5.55%) ▼|IBM247.11-7.21 (-2.84%) ▼|INTC52.25-6.02 (-10.33%) ▼|INTU354.84-1.80 (-0.50%) ▼|ISRG468.52-13.58 (-2.82%) ▼|JNJ272.32-4.00 (-1.45%) ▼|JPM337.34-14.77 (-4.19%) ▼|KO95.73-0.07 (-0.07%) ▼|LIN521.23-3.51 (-0.67%) ▼|LLY1,364.73-53.26 (-3.76%) ▼|LMT576.16-18.88 (-3.17%) ▼|LOW227.24-2.14 (-0.93%) ▼|LRCX185.20-36.23 (-16.36%) ▼|MA655.92-16.76 (-2.49%) ▼|MCD278.04-2.18 (-0.78%) ▼|MDLZ66.82-0.56 (-0.83%) ▼|MDT104.84-0.12 (-0.11%) ▼|META605.08-24.92 (-3.96%) ▼|MMM187.77-6.18 (-3.19%) ▼|MO77.58-0.43 (-0.55%) ▼|MRK146.94-3.42 (-2.27%) ▼|MS182.44-11.53 (-5.94%) ▼|MSFT535.93-19.87 (-3.58%) ▼|MU656.39-138.84 (-17.46%) ▼|NEE88.25-0.20 (-0.23%) ▼|NFLX65.56-0.83 (-1.25%) ▼|NKE39.56-0.93 (-2.30%) ▼|NOW102.36-6.45 (-5.93%) ▼|NVDA181.60-18.53 (-9.26%) ▼|ORCL115.16-8.57 (-6.93%) ▼|PEP142.71+0.29 (+0.20%) ▲|PFE29.88-0.91 (-2.96%) ▼|PG167.10-0.22 (-0.13%) ▼|PLTR154.99-16.71 (-9.73%) ▼|PM201.50-9.78 (-4.63%) ▼|QCOM156.75-16.44 (-9.49%) ▼|RTX191.88-6.55 (-3.30%) ▼|SBUX106.16-3.54 (-3.23%) ▼|SCHW92.58-0.79 (-0.85%) ▼|SO93.34+0.22 (+0.24%) ▲|SPG226.55-1.95 (-0.85%) ▼|T21.82-0.01 (-0.05%) ▼|TMO676.94-29.22 (-4.14%) ▼|TMUS160.59+1.42 (+0.89%) ▲|TSLA343.69-41.50 (-10.77%) ▼|TXN278.15-33.34 (-10.70%) ▼|UBER68.78-1.09 (-1.56%) ▼|UNH395.72-13.66 (-3.34%) ▼|UNP297.95-10.58 (-3.43%) ▼|UPS111.04-3.27 (-2.86%) ▼|USB59.75-1.28 (-2.10%) ▼|V422.59-13.98 (-3.20%) ▼|VZ46.12-0.05 (-0.11%) ▼|WFC84.80-2.63 (-3.01%) ▼|WMT127.72-1.45 (-1.12%) ▼|XOM165.30-3.97 (-2.35%) ▼|AAPL344.17-5.34 (-1.53%) ▼|ABBV288.24-6.59 (-2.24%) ▼|ABT113.60-1.91 (-1.65%) ▼|ACN265.16+0.89 (+0.34%) ▲|ADBE246.44-2.04 (-0.82%) ▼|AMAT319.25-50.15 (-13.58%) ▼|AMD404.40-84.38 (-17.26%) ▼|AMGN460.28-18.20 (-3.80%) ▼|AMT193.99-0.87 (-0.45%) ▼|AMZN260.21-5.82 (-2.19%) ▼|AVGO291.53-33.95 (-10.43%) ▼|AXP324.97-7.62 (-2.29%) ▼|BA172.50-4.50 (-2.54%) ▼|BAC49.76-1.87 (-3.62%) ▼|BKNG168.72-2.25 (-1.32%) ▼|BLK1,170.67-53.70 (-4.39%) ▼|BMY63.13-1.06 (-1.65%) ▼|BNY147.49-5.23 (-3.42%) ▼|BRK-B572.33-6.76 (-1.17%) ▼|C118.45-6.29 (-5.04%) ▼|CAT553.64-37.66 (-6.37%) ▼|CL98.69-0.07 (-0.07%) ▼|CMCSA24.95+0.10 (+0.40%) ▲|COF203.84-2.47 (-1.20%) ▼|COP135.46-1.48 (-1.08%) ▼|COST1,065.59+19.12 (+1.83%) ▲|CRM222.41-4.70 (-2.07%) ▼|CSCO95.72-7.89 (-7.62%) ▼|CVS81.33+1.37 (+1.71%) ▲|CVX212.93-4.03 (-1.86%) ▼|DE663.31-13.19 (-1.95%) ▼|DHR226.34-8.59 (-3.66%) ▼|DIS117.22-1.73 (-1.45%) ▼|DUK130.08+0.49 (+0.38%) ▲|EMR162.61-7.83 (-4.59%) ▼|FDX316.80-12.60 (-3.83%) ▼|GD356.35-8.52 (-2.34%) ▼|GE314.73-14.72 (-4.47%) ▼|GEV770.51-62.32 (-7.48%) ▼|GILD167.57-6.91 (-3.96%) ▼|GM89.33-3.10 (-3.35%) ▼|GOOG281.74-5.56 (-1.94%) ▼|GOOGL282.57-6.36 (-2.20%) ▼|GS868.95-59.05 (-6.36%) ▼|HD349.94-5.50 (-1.55%) ▼|HON215.78-12.69 (-5.55%) ▼|IBM247.11-7.21 (-2.84%) ▼|INTC52.25-6.02 (-10.33%) ▼|INTU354.84-1.80 (-0.50%) ▼|ISRG468.52-13.58 (-2.82%) ▼|JNJ272.32-4.00 (-1.45%) ▼|JPM337.34-14.77 (-4.19%) ▼|KO95.73-0.07 (-0.07%) ▼|LIN521.23-3.51 (-0.67%) ▼|LLY1,364.73-53.26 (-3.76%) ▼|LMT576.16-18.88 (-3.17%) ▼|LOW227.24-2.14 (-0.93%) ▼|LRCX185.20-36.23 (-16.36%) ▼|MA655.92-16.76 (-2.49%) ▼|MCD278.04-2.18 (-0.78%) ▼|MDLZ66.82-0.56 (-0.83%) ▼|MDT104.84-0.12 (-0.11%) ▼|META605.08-24.92 (-3.96%) ▼|MMM187.77-6.18 (-3.19%) ▼|MO77.58-0.43 (-0.55%) ▼|MRK146.94-3.42 (-2.27%) ▼|MS182.44-11.53 (-5.94%) ▼|MSFT535.93-19.87 (-3.58%) ▼|MU656.39-138.84 (-17.46%) ▼|NEE88.25-0.20 (-0.23%) ▼|NFLX65.56-0.83 (-1.25%) ▼|NKE39.56-0.93 (-2.30%) ▼|NOW102.36-6.45 (-5.93%) ▼|NVDA181.60-18.53 (-9.26%) ▼|ORCL115.16-8.57 (-6.93%) ▼|PEP142.71+0.29 (+0.20%) ▲|PFE29.88-0.91 (-2.96%) ▼|PG167.10-0.22 (-0.13%) ▼|PLTR154.99-16.71 (-9.73%) ▼|PM201.50-9.78 (-4.63%) ▼|QCOM156.75-16.44 (-9.49%) ▼|RTX191.88-6.55 (-3.30%) ▼|SBUX106.16-3.54 (-3.23%) ▼|SCHW92.58-0.79 (-0.85%) ▼|SO93.34+0.22 (+0.24%) ▲|SPG226.55-1.95 (-0.85%) ▼|T21.82-0.01 (-0.05%) ▼|TMO676.94-29.22 (-4.14%) ▼|TMUS160.59+1.42 (+0.89%) ▲|TSLA343.69-41.50 (-10.77%) ▼|TXN278.15-33.34 (-10.70%) ▼|UBER68.78-1.09 (-1.56%) ▼|UNH395.72-13.66 (-3.34%) ▼|UNP297.95-10.58 (-3.43%) ▼|UPS111.04-3.27 (-2.86%) ▼|USB59.75-1.28 (-2.10%) ▼|V422.59-13.98 (-3.20%) ▼|VZ46.12-0.05 (-0.11%) ▼|WFC84.80-2.63 (-3.01%) ▼|WMT127.72-1.45 (-1.12%) ▼|XOM165.30-3.97 (-2.35%) ▼|
20.3 C
New York
Friday, November 6, 2026

Tag: Regulatory

newsFORsourcecompanycontentinformationreleases1market

Steelmaker SSAB, the manufacturer of Hardox® wear plate, cracks down on counterfeit goods

MELBOURNE, Australia, June 23, 2025 /PRNewswire/ -- SSAB has taken decisive action against two Indian companies selling counterfeit steel. The unauthorised products, labelled with...

Novo Nordisk A/S: Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with haemophilia A in new phase 3 data...

Bagsværd, Denmark, 22 June 2025 – Novo Nordisk today presented results from the phase 3b FRONTIER5 trial showing that a direct switch to investigational Mim8 (denecimig) prophylaxis from emicizumab treatment, without a washout period or Mim8 loading dose, was well-tolerated with no safety concerns in adults and adolescents living with haemophilia A, with or without inhibitors1. Additionally, a FRONTIER5 Patient-Reported Outcomes (PROs) assessment found the Mim8 pen-injector easy to use, with an overall strong user preference for the pen-injector compared to the previous emicizumab injection system2,3. The results were presented at the International Society on Thrombosis and Haemostasis (ISTH) Congress in Washington, D.C.

Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with hemophilia A in new phase 3 data presented at the...

New FRONTIER5 results show a direct switch to investigational Mim8 (denecimig) prophylaxis treatment from emicizumab, without the need for a washout period, was well-tolerated...

Lilly’s once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials

Results from the fixed-dose QWINT-1 study, along with the QWINT-3 and QWINT-4 studies, reinforce efsitora's potential to simplify insulin management with weekly dosing Lilly plans...

Once-Weekly Insulin Efsitora Achieves Comparable A1C Reduction to Daily Insulin Therapy

Once-weekly insulin helped patients achieve an average A1C of 6.92% in QWINT-1 trial Results support once-weekly insulin as effective alternative to daily treatment CHICAGO, June 22,...

FinThrive Introduces Agentic AI at HFMA 2025 to Help Customers Transform Healthcare Revenue Cycle Management Performance

Company to also highlight advancements in denials and underpayments management and speak to the measurable impact of RCM technology adoption DENVER, June 22, 2025 /PRNewswire/...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sable Offshore Corp. – SOC

NEW YORK, June 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sable Offshore Corp. ("Sable" or the "Company")...

Pomerantz Law Firm Announces the Filing of a Class Action Against PepGen Inc. and Certain Officers – PEPG

NEW YORK, June 22, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against PepGen Inc. ("PepGen" or the "Company")...

CagriSema Demonstrates Significant Weight Loss in Adults with Obesity

Once-weekly medication results in weight loss of up to 22.7% in adults without diabetes and 15.7% in those with type 2 diabetes CHICAGO, June 22,...

FinThrive Debuts Denials and Underpayments Analyzer, a Unified Solution for Denials and Underpayments, at HFMA 2025

Next generation analyzer helps hospitals protect revenue before it's lost by delivering timely end-to-end visibility and actionable intelligence DENVER, June 22, 2025 /PRNewswire/ --...

Dr. Anosh Ahmed Advances Chicago Crypto Hub Project as Federal Support for Blockchain Grows

Dr. Anosh Ahmed repurposes West Side warehouse into blockchain innovation center, targeting 250+ jobs and tech-based economic opportunities amid pro-crypto

Dr. Anosh Ahmed Advances Chicago Crypto Hub Project Amid National Pro-Crypto Policy Shift

Dr. Anosh Ahmed converts vacant West Side warehouse into blockchain innovation hub, creating 250+ jobs and advancing tech-driven economic growth aligned with Trump administration’s pro-crypto stance. 
Dr. Anosh Ahmed converts vacant West Side warehouse into blockchain innovation hub, creating 250+ jobs and advancing tech-driven economic growth aligned with Trump administration’s pro-crypto stance.

BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions

Treatment with apelin receptor agonist enhanced glycemic control and demonstrated cardioprotective effects, with additive benefits observed in combination with incretin therapy

ROSEN, NATIONAL INVESTOR COUNSEL, Encourages PepGen Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PEPG

NEW YORK, June 21, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of PepGen Inc. (NASDAQ: PEPG) between March 7, 2024 and March 3, 2025, both dates inclusive (the “Class Period”), of the important August 8, 2025 lead plaintiff deadline.

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsRegulatory

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers